Industrial - Pollution & Treatment Controls
Compare Stocks
2 / 10Stock Comparison
TOMZ vs HROW
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
TOMZ vs HROW — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Industrial - Pollution & Treatment Controls | Drug Manufacturers - Specialty & Generic |
| Market Cap | $14M | $1.45B |
| Revenue (TTM) | $6M | $272M |
| Net Income (TTM) | $-5M | $-5M |
| Gross Margin | 39.8% | 75.1% |
| Operating Margin | -94.2% | 11.2% |
| Forward P/E | — | 82.9x |
| Total Debt | $3M | $252M |
| Cash & Equiv. | $665K | $73M |
TOMZ vs HROW — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| TOMI Environmental … (TOMZ) | 100 | 8.2 | -91.8% |
| Harrow Health, Inc. (HROW) | 100 | 721.8 | +621.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TOMZ vs HROW
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TOMZ is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta -0.06, Low D/E 73.3%, current ratio 2.39x
- Beta -0.06, current ratio 2.39x
- Lower D/E ratio (73.3% vs 483.7%)
HROW carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 36.4%, EPS growth 71.4%, 3Y rev CAGR 45.4%
- 9.1% 10Y total return vs TOMZ's -80.3%
- 36.4% revenue growth vs TOMZ's 5.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 36.4% revenue growth vs TOMZ's 5.2% | |
| Quality / Margins | -1.9% margin vs TOMZ's -91.4% | |
| Stability / Safety | Lower D/E ratio (73.3% vs 483.7%) | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +58.8% vs TOMZ's -14.6% | |
| Efficiency (ROA) | -1.4% ROA vs TOMZ's -64.6%, ROIC 9.5% vs -39.7% |
TOMZ vs HROW — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TOMZ vs HROW — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
HROW leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
HROW is the larger business by revenue, generating $272M annually — 47.9x TOMZ's $6M. HROW is the more profitable business, keeping -1.9% of every revenue dollar as net income compared to TOMZ's -91.4%. On growth, HROW holds the edge at +33.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $6M | $272M |
| EBITDAEarnings before interest/tax | -$5M | $59M |
| Net IncomeAfter-tax profit | -$5M | -$5M |
| Free Cash FlowCash after capex | -$723,605 | $73M |
| Gross MarginGross profit ÷ Revenue | +39.8% | +75.1% |
| Operating MarginEBIT ÷ Revenue | -94.2% | +11.2% |
| Net MarginNet income ÷ Revenue | -91.4% | -1.9% |
| FCF MarginFCF ÷ Revenue | -12.7% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -20.9% | +33.3% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -5.3% |
Valuation Metrics
TOMZ leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $14M | $1.5B |
| Enterprise ValueMkt cap + debt − cash | $17M | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -3.22x | -278.93x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 82.86x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.83x | 5.34x |
| Price / BookPrice ÷ Book value/share | 3.46x | 27.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
HROW leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HROW delivers a -10.1% return on equity — every $100 of shareholder capital generates $-10 in annual profit, vs $-2 for TOMZ. TOMZ carries lower financial leverage with a 0.73x debt-to-equity ratio, signaling a more conservative balance sheet compared to HROW's 4.84x. On the Piotroski fundamental quality scale (0–9), HROW scores 4/9 vs TOMZ's 2/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -10.1% |
| ROA (TTM)Return on assets | -64.6% | -1.4% |
| ROICReturn on invested capital | -39.7% | +9.5% |
| ROCEReturn on capital employed | -44.9% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.73x | 4.84x |
| Net DebtTotal debt minus cash | $2M | $179M |
| Cash & Equiv.Liquid assets | $664,879 | $73M |
| Total DebtShort + long-term debt | $3M | $252M |
| Interest CoverageEBIT ÷ Interest expense | -10.20x | 0.53x |
Total Returns (Dividends Reinvested)
HROW leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HROW five years ago would be worth $47,797 today (with dividends reinvested), compared to $2,237 for TOMZ. Over the past 12 months, HROW leads with a +58.8% total return vs TOMZ's -14.6%. The 3-year compound annual growth rate (CAGR) favors HROW at 12.7% vs TOMZ's 4.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -10.3% | -21.8% |
| 1-Year ReturnPast 12 months | -14.6% | +58.8% |
| 3-Year ReturnCumulative with dividends | +12.5% | +43.0% |
| 5-Year ReturnCumulative with dividends | -77.6% | +378.0% |
| 10-Year ReturnCumulative with dividends | -80.3% | +914.3% |
| CAGR (3Y)Annualised 3-year return | +4.0% | +12.7% |
Risk & Volatility
Evenly matched — TOMZ and HROW each lead in 1 of 2 comparable metrics.
Risk & Volatility
TOMZ is the less volatile stock with a -0.06 beta — it tends to amplify market swings less than HROW's 2.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HROW currently trades 71.2% from its 52-week high vs TOMZ's 59.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.06x | 2.13x |
| 52-Week HighHighest price in past year | $1.20 | $54.85 |
| 52-Week LowLowest price in past year | $0.50 | $21.12 |
| % of 52W HighCurrent price vs 52-week peak | +59.1% | +71.2% |
| RSI (14)Momentum oscillator 0–100 | 52.9 | 54.6 |
| Avg Volume (50D)Average daily shares traded | 404K | 733K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $75.67 |
| # AnalystsCovering analysts | — | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
HROW leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TOMZ leads in 1 (Valuation Metrics). 1 tied.
TOMZ vs HROW: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TOMZ or HROW a better buy right now?
For growth investors, Harrow Health, Inc.
(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus 5. 2% for TOMI Environmental Solutions, Inc. (TOMZ). Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TOMZ or HROW?
Over the past 5 years, Harrow Health, Inc.
(HROW) delivered a total return of +378. 0%, compared to -77. 6% for TOMI Environmental Solutions, Inc. (TOMZ). Over 10 years, the gap is even starker: HROW returned +914. 3% versus TOMZ's -80. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TOMZ or HROW?
By beta (market sensitivity over 5 years), TOMI Environmental Solutions, Inc.
(TOMZ) is the lower-risk stock at -0. 06β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately -3611% more volatile than TOMZ relative to the S&P 500. On balance sheet safety, TOMI Environmental Solutions, Inc. (TOMZ) carries a lower debt/equity ratio of 73% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TOMZ or HROW?
By revenue growth (latest reported year), Harrow Health, Inc.
(HROW) is pulling ahead at 36. 4% versus 5. 2% for TOMI Environmental Solutions, Inc. (TOMZ). On earnings-per-share growth, the picture is similar: Harrow Health, Inc. grew EPS 71. 4% year-over-year, compared to -29. 4% for TOMI Environmental Solutions, Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TOMZ or HROW?
Harrow Health, Inc.
(HROW) is the more profitable company, earning -1. 9% net margin versus -57. 8% for TOMI Environmental Solutions, Inc. — meaning it keeps -1. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HROW leads at 11. 2% versus -53. 0% for TOMZ. At the gross margin level — before operating expenses — HROW leads at 75. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TOMZ or HROW?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TOMZ or HROW better for a retirement portfolio?
For long-horizon retirement investors, TOMI Environmental Solutions, Inc.
(TOMZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 06)). Harrow Health, Inc. (HROW) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TOMZ: -80. 3%, HROW: +914. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TOMZ and HROW?
These companies operate in different sectors (TOMZ (Industrials) and HROW (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: TOMZ is a small-cap quality compounder stock; HROW is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.